Antares Pharma Inc

Antares Pharma — Raymond James Life Sciences & MedTech Conference 2019

24 slides from Antares Pharma's conference presentation, Jun 18, 2019

  1. Slide 1: Raymond James Life Sciences & MedTech Conference

    NASDAQ: ATRS Raymond James Life Sciences & MedTech Conference June 18, 2019 Robert F. Apple President & Chief Executive Officer Exhibit 99.1

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ mate

  3. Slide 3: Antares Pharma: An Innovative Leader in Self-Administered Injection Technology

    Antares Pharma An Innovative Leader in Self-Administered Injection Technology – Five products utilizing ATRS devices FDA approved in the past five years and three in 2018 - Makena® SC AI, Generic EpiPen® and XYOSTED™ A Growing Combination Drug Device Company with 2018 Revenue of $63.6 Million Q119 r

  4. Slide 4: Antares Proprietary Commercial Products

    NASDAQ: ATRS Antares Proprietary Commercial Products

  5. Slide 5: XYOSTED Product Features

    PRODUCT FEATURES Easy to use and store at room temperature Fine (27-gauge) needle allows for rapid subcutaneous delivery of sesame oil solution (~10 seconds) Locking needle guard hides needle before, during, and after administration and reduces risk of needle stick injuries TE, testosterone enanthat

  6. Slide 6: Ctrough Stable For Weeks

    Ctrough Stable For 52 Weeks Mean Ctrough (ng/dL) over 52 week “003” study 6 12 18 26 38 52 Week 1, pre-dose QST-13-003 treatment regimen demonstrated a mean steady state concentration of testosterone of 553.3 ± 127.3 ng/dL at 12 weeks Orange lines represent the defined range of 300 – 1100 ng/dL . .

  7. Slide 7: Unique Messaging: 98.5% of P3 XYOSTED Patients in Physiologic Range

    Unique Messaging: 98.5% of P3 XYOSTED™ patients achieved levels in the physiologic range With XYOSTED™, consistent steady state, physiologic levels are achieved in 6 weeks and then maintained over a year in the P3 study In a P3 clinical study, 99.4% of observed injections were virtually pain-free Co

  8. Slide 8: The New Way to Deliver TRT

    >5500 PATIENTS have been prescribed XYOSTED by ~1800 HCP’s The NEW Way to Deliver TRT EASE OF USE STEADY LEVELS WEEKLY DOSING VIRTUALLY PAIN FREE

  9. Slide 9: Working Through the Toughest Part of the Year: New Patient Starts

    WE ARE WORKING THROUGH THE TOUGHEST PART OF THE YEAR! 45% of XYOSTED business is Coming From New Patient Starts* and is Increasing 9

  10. Slide 10: Broad Utilization Across all TRT Specialties

    WE ARE WORKING THROUGH THE TOUGHEST PART OF THE YEAR! Broad Utilization Across all TRT Specialties 10

  11. Slide 11: XYOSTED Monthly Prescription Trends

    XYOSTED™ Monthly Prescription Trends Source: Symphony/Bloomberg Monthly Data 2,200 1710 Week Ended June 7 – XYOSTED™ TRX’s = 1000

  12. Slide 12: TRT Market Monthly Trend – May 2019

    TRT MARKET Monthly Trend – May 2019 Source - IQVIA™

  13. Slide 13: ATRS Commercial Products

    ATRS Commercial Products OTREXUP® (methotrexate) injection Sumatriptan Injection USP OTREXUP® and Sumatriptan combined 2018 revenue - $29 million Q119 combined revenue - $7.5 million

  14. Slide 14: Antares Partnered Commercial Products

    NASDAQ: ATRS Antares Partnered Commercial Products

  15. Slide 15: Teva's Epinephrine Injection USP Approved Utilizing ATRS VIBEX Device

    Teva’s Epinephrine Injection USP Approved Utilizing ATRS VIBEX® Device Teva’s generic EpiPen® was approved by FDA and made commercially available in limited quantities November 2018 – therapeutically equivalent and fully substitutable at the pharmacy Teva continues to manufacture drug and build supp

  16. Slide 16: Generic EpiPen Monthly Prescription Trends

    Generic EpiPen® Monthly Prescription Trends Source: Symphony/Bloomberg Monthly Data

  17. Slide 17: Makena Utilizing ATRS QuickShot Device

    Makena® hydroxyprogesterone caproate injection Utilizing ATRS QuickShot® Device Subcutaneous injection Intramuscular injection Efficient Discreet Administration friendly ü ü ü Makena® - Used to Reduce the Risk of Preterm Birth in Certain At-Risk Women Q119 AMAG SC auto injector revenue of $37.8M – S

  18. Slide 18: Antares Development Pipeline

    NASDAQ: ATRS Antares Development Pipeline

  19. Slide 19: Antares Development Pipeline

    Antares Development Pipeline Product Preclinical Phase 1 Phase 2 Phase 3 Marketed Antares Proprietary and Partnered Products Teriparatide - Teva Exenatide - Teva ATRS-1701 - Neurology Methotrexate – Ectopic Pregnancy – (Orphan Status) Rescue Pen - Pfizer

  20. Slide 20: ATRS Q1 2019 Results

    NASDAQ: ATRS ATRS Q1 2019 Results

  21. Slide 21: Q119 Significant Financial and Operational Achievements

    Q119 Significant Financial and Operational Achievements Record quarterly revenue of $23.3 million – an 83% increase vs. Q118 $18.3 million in product revenue – a 67% increase as compared to the same period one year ago Commercialized Proprietary Products: OTREXUP®, Sumatriptan, XYOSTED™ - $8.2M Part

  22. Slide 22: ATRS Projected Five Year Revenue Growth

    ATRS Projected Five Year Revenue Growth Projected CAGR – 30.4% Guidance +14% vs. ‘15 +72% vs. ‘14 +17% vs. ‘17 +49% - 65% vs. ’18* * Percent increase based on 2019 guidance

  23. Slide 23: ATRS – 2019 Potential Catalysts

    ATRS – 2019 Potential Catalysts XYOSTED™ prescription growth Generic EpiPen® prescription growth Contribution from the Makena® SC auto injector product U.S. FDA approval and global launch of generic Forteo® 23

  24. Slide 24: Raymond James Life Sciences & MedTech Conference

    NASDAQ: ATRS Raymond James Life Sciences & MedTech Conference June 18, 2019 Robert F. Apple President & Chief Executive Officer

Antares Pharma — Raymond James Life Sciences & MedTech Conference 2019 on 6ix